| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CONSUN PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 12:28 | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 28.04. | CONSUN PHARMA (01681): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 28.04. | CONSUN PHARMA (01681): ANNUAL REPORT 2025 | 4 | HKEx | ||
| 28.04. | CONSUN PHARMA (01681): NOTIFICATION LETTER TO SHAREHOLDERS - ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 28.04. | CONSUN PHARMA (01681): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 28.04. | CONSUN PHARMA (01681): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 28.04. | CONSUN PHARMA (01681): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS, (2) PROPOSED FINAL DIVIDEND, (3) PROPOSED RE-APPOINTMENT OF AUDITOR, (4) PROPOSED ... | 2 | HKEx | ||
| 26.03. | Consun Pharmaceutical Group Limited Reveals Advance In Full Year Profit | 6 | RTTNews | ||
| 26.03. | CONSUN PHARMA (01681): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 | 13 | HKEx | ||
| 26.03. | CONSUN PHARMA (01681): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 4 | HKEx | ||
| 05.03. | CONSUN PHARMA (01681): NOTICE OF BOARD MEETING | 8 | HKEx | ||
| 13.02. | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.01. | CONSUN PHARMA (01681): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE PROGRAM UNDER THE REPURCHASE MANDATE | 1 | HKEx | ||
| 19.01. | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 06.01. | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 23.12.25 | CONSUN PHARMA (01681): TERMS OF REFERENCE OF THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 23.12.25 | CONSUN PHARMA (01681): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 23.12.25 | CONSUN PHARMA (01681): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 23 DECEMBER 2025 | 3 | HKEx | ||
| 10.12.25 | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): 2025 SHARE AWARD SCHEME | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 121,70 | +0,81 % | DAX-Check LIVE: Auto1, Brenntag, E.on, Merck, RWE, SFC Energy, SMA Solar, Verbio im Fokus | Die festgefahrene Lage im Nahen Osten hat den deutschen Aktienmarkt weiter belastet. Je länger der Konflikt andauert, desto größer werden die Sorgen vor wirtschaftlichen Folgen. Steigende Ölpreise und... ► Artikel lesen | |
| GILEAD SCIENCES | 112,72 | +0,25 % | Gilead Sciences, Inc.: Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 | - Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen Evidence of... ► Artikel lesen | |
| TEVA | 29,300 | -0,34 % | Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant... ► Artikel lesen | |
| DERMAPHARM | 49,100 | +1,34 % | Ihre wichtigsten Termine: Frische Q-Zahlen von Cisco, Porsche, Dermapharm, Siemens, Deutsche Telekom & Eon | © Foto: Thiago Prudencio/DAX via ZUMA Press Wire/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| SINOPHARM | 1,970 | -0,51 % | Sinopharm expands its international presence | ||
| SANTHERA PHARMACEUTICALS | 18,120 | +1,34 % | Santhera Pharmaceuticals Holding AG: Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung | Ad-hoc-Mitteilung gemäss Art. 53 KR.
Pratteln, Schweiz, 5. Mai 2026 - Santhera Pharmaceuticals (SIX: SANN) hat heute die Einladung zur ordentlichen Generalversammlung (GV) veröffentlicht, die am... ► Artikel lesen | |
| CSPC PHARMA | 0,824 | +1,07 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2095 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | ||
| WUXI BIOLOGICS | 3,655 | +1,67 % | WUXI BIO (02269): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 10, 2026 | ||
| OPKO HEALTH | 0,947 | 0,00 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| COSMO | 85,40 | +1,30 % | Cosmo Pharmaceuticals N.V.: Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program | Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) ("Cosmo" or "the Company") today announced the completion of patient enrolment in its Phase II clinical... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 1,921 | +0,79 % | Fosun Pharma, AriBio Sign Exclusive Global Option Agreement | ||
| GEDEON RICHTER | 34,420 | +0,35 % | Gedeon Richter Plc.: Transactions with Treasury Shares | ||
| BAYER | 38,750 | +0,60 % | Übernahme bei Bayer! Schock bei Rheinmetall! Chance bei MustGrow Aktie! | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die Blockade in der Straße von Hormus ist ein Stresstest für die globale Ernährungssicherheit. Die Lieferketten der Düngemittelindustrie... ► Artikel lesen | |
| NOVO NORDISK | 38,350 | +0,04 % | JEFFERIES stuft NOVO NORDISK auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Beim Pharmakonzern gebe es "so viele Fragen... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 32,860 | -0,09 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen |